ESR1 and triple-negative breast carcinoma: As an additional significant finding, a combination of rosiglitazone and 4-OHTAM was also effective in inhibiting cell proliferation and tumor growth in cells that do not express ER and overexpress ACSL4, such as the very aggressive triple negative breast cancer cell line MDA-MB-231.